Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Aldeyra Therapeutics brings biotech CFO experience to board amid ALDX regulatory reset
Find out how Aldeyra Therapeutics’ new board appointment could shape ALDX stock sentiment, FDA strategy and reproxalap’s next chapter for investors now.
$IMU rises after Imugene wins FDA Fast Track status for allogeneic CAR T therapy in CLL and MZL
Imugene won FDA Fast Track status for azer-cel in blood cancers. Find out what the $IMU regulatory boost means for investors.
Tango Therapeutics (TNGX) soars on striking pancreatic cancer data, then moves to cash in
Tango Therapeutics soared 50%+ on early pancreatic cancer data, a 92% response rate for vopimetostat plus daraxonrasib, then filed a $500M offering to cash in.
Pfizer (PFE) tests investor patience as berobenatide moves toward Phase 3 obesity trials
Find out how Pfizer’s berobenatide data could reshape its obesity drug strategy, GLP-1 competition and investor sentiment today!
Corcept Therapeutics (CORT) CATALYST data puts Korlym at centre of difficult-to-control diabetes strategy
Find out how Corcept Therapeutics’ ADA data could reshape cortisol screening in hard-to-control diabetes and GLP-1 care.
Incyte stock in focus as $2bn Star Therapeutics deal nears for blood disorder pipeline
Incyte may buy Star Therapeutics for up to $2B. See why the deal matters for Jakafi risk and hematology growth.
Trevi Therapeutics (NASDAQ: TRVI) bets everything on two Phase 3 chronic cough trials
Trevi Therapeutics (NASDAQ: TRVI) has no revenue and is up 71%, yet its future rides on two Phase 3 cough trials that do not read out until 2027.
Eli Lilly’s oral GLP-1 Foundayo gains new women’s health angle with menopause weight-loss data
Lilly’s oral GLP-1 now targets menopause-linked weight gain. Read why Foundayo could sharpen the next obesity drug battleground.
Why the THIO-104 Phase 3 trial could become the most important milestone in MAIA Biotechnology’s history
Find out how MAIA Biotechnology’s ateganosine trial progress could reshape its lung cancer strategy and investor sentiment.
Could pediatric diabetes demand unlock new commercial momentum for MannKind Corporation’s Afrezza?
Find out how Afrezza’s pediatric FDA approval could strengthen MannKind’s growth story and reshape investor sentiment today.